Literature DB >> 24114415

Feedback modeling of non-esterified fatty acids in obese Zucker rats after nicotinic acid infusions.

Christine Ahlström1, Tobias Kroon, Lambertus A Peletier, Johan Gabrielsson.   

Abstract

This study investigates the impact of disease on nicotinic acid (NiAc)-induced changes in plasma concentrations of non-esterified fatty acids (NEFA). NiAc was given by constant intravenous infusion to normal Sprague-Dawley and obese Zucker rats, and arterial blood samples were taken for analysis of NiAc, NEFA, insulin and glucose plasma concentrations. The intravenous route was intentionally selected to avoid confounding processes, such as absorption, following extravascular administration. Data were analyzed using nonlinear mixed effects modeling (NONMEM, version VI). The disposition of NiAc in the normal rats was described by a two-compartment model with endogenous synthesis of NiAc and two parallel capacity-limited elimination processes. In the obese rats disposition was described by a one-compartment model with endogenous synthesis of NiAc and one capacity-limited elimination process. The plasma concentration of NiAc drove NEFA (R) turnover via an inhibitory drug-mechanism function acting on the formation of NEFA. NEFA turnover was described by a feedback model with a moderator distributed over a series of transit compartments, where the first compartment (M 1 ) inhibited the formation of R and the last compartment (M N ) stimulated the loss of R. All processes regulating plasma NEFA concentrations were assumed to be captured by the moderator function. Differences in the pharmacodynamic response of the two strains included, in the obese animals, an increased NEFA baseline, diminished rebound and post-rebound oscillation, and a more pronounced slowly developing tolerance during the period of constant drug exposure. The feedback model captured the NiAc-induced changes in NEFA response in both the normal and obese rats. Differences in the parameter estimates between the obese and normal rats included, in the former group, increases in R 0 , k in and p by 44, 41 and 78 %, respectively, and decreases in k out and γ by 64 and 84 %, respectively. The estimates of k tol and IC 50 were similar in both groups. The NiAc-NEFA concentration-response relationship at equilibrium was substantially different in the two groups, being shifted upwards and to the right, and being shallower in the obese rats. The extent of such shifts is important, as they demonstrate the impact of disease at equilibrium and, if ignored, will lead to erroneous dose predictions and, in consequence, poorly designed studies. The proposed models are primarily aimed at screening and selecting candidates with the highest potential of becoming a viable drug in man.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24114415     DOI: 10.1007/s10928-013-9335-z

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  57 in total

1.  Permanent cannulation of aorta and vena cava in rats and ground squirrels.

Authors:  V POPOVIC; P POPOVIC
Journal:  J Appl Physiol       Date:  1960-07       Impact factor: 3.531

2.  Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure.

Authors:  U Elkayam; D Kulick; N McIntosh; A Roth; W Hsueh; S H Rahimtoola
Journal:  Circulation       Date:  1987-09       Impact factor: 29.690

3.  GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus.

Authors:  R L Dobbins; S P Shearn; R L Byerly; F F Gao; K M Mahar; A Napolitano; G J Nachbaur; A-C Le Monnier de Gouville
Journal:  Diabetes Obes Metab       Date:  2013-06-12       Impact factor: 6.577

4.  Theophylline disposition in obese rats.

Authors:  L Shum; W J Jusko
Journal:  J Pharmacol Exp Ther       Date:  1984-02       Impact factor: 4.030

5.  Severe hepatic and peripheral insulin resistance as evidenced by euglycemic clamps in genetically obese fa/fa rats.

Authors:  J Terrettaz; F Assimacopoulos-Jeannet; B Jeanrenaud
Journal:  Endocrinology       Date:  1986-02       Impact factor: 4.736

6.  Insulin and obesity in the Zucker genetically obese rat "fatty".

Authors:  L M Zucker; H N Antoniades
Journal:  Endocrinology       Date:  1972-05       Impact factor: 4.736

Review 7.  Effect of obesity on the pharmacokinetics of drugs in humans.

Authors:  Michael J Hanley; Darrell R Abernethy; David J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

8.  Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man.

Authors:  S M Grundy; H Y Mok; L Zech; M Berman
Journal:  J Lipid Res       Date:  1981-01       Impact factor: 5.922

9.  Effectiveness of low-dose crystalline nicotinic acid in men with low high-density lipoprotein cholesterol levels.

Authors:  R Martin-Jadraque; F Tato; J M Mostaza; G L Vega; S M Grundy
Journal:  Arch Intern Med       Date:  1996-05-27

10.  Diurnal changes in serum metabolites and hormones in lean and obese Zucker rats.

Authors:  R J Martin; P J Wangsness; J H Gahagan
Journal:  Horm Metab Res       Date:  1978-05       Impact factor: 2.936

View more
  7 in total

1.  Modeling energy intake by adding homeostatic feedback and drug intervention.

Authors:  Peter Gennemark; Stephan Hjorth; Johan Gabrielsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-11-12       Impact factor: 2.745

2.  Feedback control indirect response models.

Authors:  Yaping Zhang; David Z D'Argenio
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-07-09       Impact factor: 2.745

3.  Nicotinic acid timed to feeding reverses tissue lipid accumulation and improves glucose control in obese Zucker rats[S].

Authors:  Tobias Kroon; Tania Baccega; Arne Olsén; Johan Gabrielsson; Nicholas D Oakes
Journal:  J Lipid Res       Date:  2016-11-15       Impact factor: 5.922

4.  Dosing profile profoundly influences nicotinic acid's ability to improve metabolic control in rats.

Authors:  Tobias Kroon; Ann Kjellstedt; Pia Thalén; Johan Gabrielsson; Nicholas D Oakes
Journal:  J Lipid Res       Date:  2015-07-13       Impact factor: 5.922

5.  Mixed Effects Modeling Using Stochastic Differential Equations: Illustrated by Pharmacokinetic Data of Nicotinic Acid in Obese Zucker Rats.

Authors:  Jacob Leander; Joachim Almquist; Christine Ahlström; Johan Gabrielsson; Mats Jirstrand
Journal:  AAPS J       Date:  2015-02-19       Impact factor: 4.009

6.  Joint feedback analysis modeling of nonesterified fatty acids in obese Zucker rats and normal Sprague-Dawley rats after different routes of administration of nicotinic acid.

Authors:  Sofia Tapani; Joachim Almquist; Jacob Leander; Christine Ahlström; Lambertus A Peletier; Mats Jirstrand; Johan Gabrielsson
Journal:  J Pharm Sci       Date:  2014-07-01       Impact factor: 3.534

7.  Modeling of free fatty acid dynamics: insulin and nicotinic acid resistance under acute and chronic treatments.

Authors:  Robert Andersson; Tobias Kroon; Joachim Almquist; Mats Jirstrand; Nicholas D Oakes; Neil D Evans; Michael J Chappel; Johan Gabrielsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-21       Impact factor: 2.745

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.